REFINE has been featured on the latest episode of the Trial Talk Podcast. This episode explores how the REFINE trial aims to improve the use of immunotherapy to treat cancer.    Sophie Merrick, a Clinical Fellow from the MRC CTU at UCL, talks about the challenges of using immunotherapy drugs and how REFINE is testing whether giving these drugs less frequently can still treat t ...

The REFINE Protocol Paper has now been published, you can read it here: https://www.sciencedirect.com/science/article/pii/S1551714422003561 In this publication we communicate the methods, design, and goals of the REFINE trial ...

The melanoma cohort of REFINE has opened to participants. The REFINE trial is looking at whether giving immunotherapy less often is as effective at treating advanced cancer than the current treatment. It will look initially at patients with kidney (renal) and melanoma cancers.     Immunotherapy is a type of cancer treatment that uses drugs called checkpoint inhibitors. Checkp ...

Sophie Merrick presented the REFINE trial at the European Society for Medical Oncology (ESMO) Congress in Paris on the 12th September. The REFINE trial is testing different time intervals of treatment using checkpoint inhibitors, to treat different types of cancers (renal, melanoma and colorectal). The REFINE renal cancer cohort opened to recruitment on the 25th May 2022 an ...

REFINE recruited its first patient on 22/08/2022.